IRADIMED (IRMD): Evaluating Valuation After Raised 2025 Outlook and Strong Q3 Results

Simply Wall St.

11/08

IRADIMED (IRMD) just announced its third quarter results, showing year-over-year growth in both revenue and net income. The company also lifted its outlook for full-year 2025, signaling confidence ...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581818832"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581818832\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581818832?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2025-11-08 04:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581818832","market":"nz","top_or_hot":-1,"title":"IRADIMED (IRMD): Evaluating Valuation After Raised 2025 Outlook and Strong Q3 Results","media":"Simply Wall St.","content":"<div>\n<p>IRADIMED (IRMD) just announced its third quarter results, showing year-over-year growth in both revenue and net income. The company also lifted its outlook for full-year 2025, signaling confidence ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-irmd/iradimed/news/iradimed-irmd-evaluating-valuation-after-raised-2025-outlook\">網頁鏈接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IRADIMED (IRMD): Evaluating Valuation After Raised 2025 Outlook and Strong Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIRADIMED (IRMD): Evaluating Valuation After Raised 2025 Outlook and Strong Q3 Results\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2025-11-08 04:32</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>IRADIMED (IRMD) just announced its third quarter results, showing year-over-year growth in both revenue and net income. The company also lifted its outlook for full-year 2025, signaling confidence ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-irmd/iradimed/news/iradimed-irmd-evaluating-valuation-after-raised-2025-outlook\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-irmd/iradimed/news/iradimed-irmd-evaluating-valuation-after-raised-2025-outlook\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRMD","symbol_name":"iRadimed Corporation","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-irmd/iradimed/news/iradimed-irmd-evaluating-valuation-after-raised-2025-outlook","article_id":"2581818832","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-irmd/iradimed/news/iradimed-irmd-evaluating-valuation-after-raised-2025-outlook","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2581818832","pubTimestamp":1762547569,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"IRADIMED (IRMD) just announced its third quarter results, showing year-over-year growth in both revenue and net income. The company also lifted its outlook for full-year 2025, signaling confidence heading into next year.\nSee our latest analysis for IRADIMED.\nThat wave of optimism is already showing up in IRADIMED’s share price. After management lifted its full-year outlook and delivered higher earnings, the 7-day share price return clocked in at 10.17%, capping a year-to-date share price gain...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRMD":"iRadimed Corporation","BK4082":"医疗保健设备"},"translate_title":"IRADIMED(IRMD)：在上调2025年前景和强劲的第三季度业绩后评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRMD":1.5},"content_text":"IRADIMED (IRMD) just announced its third quarter results, showing year-over-year growth in both revenue and net income. The company also lifted its outlook for full-year 2025, signaling confidence heading into next year. See our latest analysis for IRADIMED. That wave of optimism is already showing up in IRADIMED’s share price. After management lifted its full-year outlook and delivered higher earnings, the 7-day share price return clocked in at 10.17%, capping a year-to-date share price gain of 54.02%. On a longer horizon, shareholders have seen a total return of over 300% in the past five years. This suggests the stock’s momentum is alive and well as the company's growth story continues to unfold. If this kind of consistent performance has you curious about other opportunities in the sector, discover what’s happening with leaders in medical devices and diagnostics using our See the full list for free.. But with shares not far from analyst targets and after such a big run-up, is IRADIMED underappreciated, or are investors already paying today for tomorrow’s growth potential? AdvertisementMost Popular Narrative: 2.6% Overvalued With IRADIMED’s share price recently closing at $84.62, slightly above the widely-followed narrative fair value of $82.50, investors are navigating a valuation that is just above consensus. This close gap sets up an open debate about whether expectations have run too far ahead of reality.  The introduction and FDA approval of the new 3870 MRI-compatible IV pump, with significantly enhanced usability and technology over the legacy product, is expected to catalyze a major replacement cycle among hospitals and imaging centers. This could unlock large-scale, recurring device and consumable revenues. This supports a step-change in revenue growth as existing customers upgrade and potential new customers previously deterred by usability issues are attracted.  Read the complete narrative. What’s powering this price? The narrative hints at a technology leap that could unlock faster growth and higher margins than IRADIMED has ever seen. But just how bold are the financial forecasts at the heart of this valuation? Get the full story behind the big numbers. Result: Fair Value of $82.50 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, risks such as concentrated reliance on the MRI pump line or any delays in customer adoption could quickly challenge the current upbeat outlook. Find out about the key risks to this IRADIMED narrative.  Build Your Own IRADIMED Narrative If you want to dig into the numbers and shape your own perspective, it's easy to build a custom narrative tailored to your view. Do it your way. A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding IRADIMED. Looking for more investment ideas? Don't let another great opportunity slip by while you focus on just one stock. Broaden your strategy and find companies shaping tomorrow's markets using these powerful research shortcuts:  Tap into the future of healthcare by zeroing in on real-world innovation with these 32 healthcare AI stocks that are advancing AI-driven patient care and diagnostics. Boost your regular income by targeting these 17 dividend stocks with yields > 3% offering robust yields and steady cash flow, setting up your portfolio for long-term resilience. Catalyze your next investment move by finding value in these 860 undervalued stocks based on cash flows trading below their estimated fair value and giving you a potential edge others might overlook.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}